Research graph
References from “The injection gives freedom” - An exploration of long-acting injectable HIV treatment acceptance among patients seeking care in two Nairobi tertiary hospitals. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
2019 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
External reference
Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: A systematic review
10.1136/bmjgh-2016-000125 · 2016 · External reference
A qualitative assessment of barriers to antiretroviral therapy adherence among adolescents in western Kenya
10.1080/15381501.2012.754392 · 2014 · External reference
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
10.1056/nejmoa1904398 · 2020 · External reference
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: Week 124 results of the open-label phase 3 FLAIR study
10.1016/s2352-3018(21)00184-3 · 2021 · External reference
Acceptability of long-acting injectable antiretroviral treatment for HIV management: Perspectives of patients and physicians in Spain
10.1089/apc.2024.0093 · 2024 · External reference
Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort
10.1007/s40121-023-00890-2 · 2023 · External reference
Barriers to uptake of long-acting antiretroviral products for treatment and prevention of human immunodeficiency virus (HIV) in high-income countries
10.1093/cid/ciac716 · 2022 · External reference
Long-acting injectable antiretroviral treatment acceptability and preferences: A qualitative study among US providers, adults living with HIV, and parents of youth living with HIV
10.1089/apc.2018.0198 · 2019 · External reference
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
10.1016/s0140-6736(17)31917-7 · 2017 · External reference
Perspectives of people living with HIV‐1 on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings: Results from the CUSTOMIZE hybrid III implementation‐effectiveness study
10.1002/jia2.26006 · 2022 · External reference
Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: Perspectives of health care providers participating in phase 3 trials
10.1186/s12913-021-06214-9 · 2021 · External reference
A dream come true: Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania
10.1371/journal.pone.0234666 · 2020 · External reference
Discontinuation of long-acting injectable cabotegravir-rilpivirine in a large clinic cohort
10.1093/ofid/ofaf600 · 2025 · External reference
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): A multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
10.1016/s2352-3018(17)30068-1 · 2017 · External reference
Long-acting injectable antiretroviral treatment: Experiences of people with HIV and their healthcare providers in Uganda
10.1186/s12879-024-09748-5 · 2024 · External reference
Factors associated with preferences for long-acting injectable antiretroviral therapy among adolescents and young people living with HIV in South Africa
10.1007/s10461-022-03949-2 · 2023 · External reference
Bridging the gap: Identifying barriers and strategies for widespread implementation of long-acting injectable antiretroviral therapy in Sub-Saharan Africa: A scoping review
10.1186/s12879-025-10871-0 · 2025 · External reference
The updated Consolidated Framework for Implementation Research based on user feedback
10.1186/s13012-022-01245-0 · 2022 · External reference
How to calculate sample size for different study designs in medical research?
10.4103/0253-7176.116232 · 2013 · External reference
“Lighten this burden of ours”: Acceptability and preferences regarding injectable antiretroviral treatment among adults and youth living with HIV in Coastal Kenya
10.1177/23259582211000517 · 2021 · External reference
A Qualitative framework for collecting and analyzing data in focus group research
10.1177/160940690900800301 · 2009 · External reference
“She is the one who knows”: A qualitative exploration of oral and injectable PrEP as part of a community empowerment approach to HIV prevention among female sex workers in the Dominican Republic and Tanzania
10.1371/journal.pgph.0000981 · 2022 · External reference
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: A secondary analysis of the HPTN 077 trial
10.1016/s2352-3018(20)30106-5 · 2020 · External reference
High Prevalence of NRTI and NNRTI Drug Resistance Among ART-Experienced, Hospitalized Inpatients
10.1097/qai.0000000000002689 · 2021 · External reference
